Back

Incidence, predictors, and success of ventricular tachycardia catheter ablation in arrhythmogenic right ventricular cardiomyopathy (ARVC): A long-term cohort study from the Nordic ARVC registry

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Arrhythmia in cardiomyopathy Ablation of Ventricular Arrhythmias ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Morten Krogh Christiansen

Viborg Hospital, Viborg (Denmark)

9 More presentations in this session

Presentation thumbnail
Future risk of bradyarrhythmias in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator indication
Doctor K. Nakasuka (Suita, JP)
Abstract Slides
Presentation thumbnail
Dilated cardiomyopathy - a group that does not benefit from ICD?
Doctor P. Silverio Antonio (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy - data from the German device Registry
Professor G. Frommeyer (Munster, DE)
Abstract
Presentation thumbnail
Incidence of appropriate implantable cardioverter defibrillator therapy and sudden cardiac death in cardiac sarcoidosis - a systematic review and meta-analysis
Mr K. Franke (Adelaide, AU)
Abstract Slides
Presentation thumbnail
Assessment of clinical risk factors for all-cause mortality among hypertrophic cardiomyopathy patients with ICDs.
Mr S. Mielczarek (Warsaw, PL)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Arrhythmia in cardiomyopathy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources